Our results point to a potential clinical benefit of introducing PD-L1/PD-1 checkpoint blockade into chemotherapy regimens for patients with NPC and suggest that the adoptive transfer of activated NK cells could be beneficial in this setting. The gene discussed is PDCD1; the disease is nasopharyngeal carcinoma.